Asahi Kasei Pharma Corp. v. Actelion Ltd. Verdict: When Business Development Deals Go Wrong

Morgan Lewis and Merrill DataSite invite you to an engaging discussion on what can happen when business development deals go wrong, how to spot a potential breach of license, and what to do when litigation is imminent.

Morgan Lewis Litigation partners will share their experiences from a recently won licensing case with antitrust overtones. After a three-month trial, a California state court jury ordered Actelion Ltd. to pay Asahi Kasei Pharma Corp. $550 million in damages for interrupting an Asahi licensing agreement to develop hypertension drug Fasudil.

Presenters:

Rollin Chippey
Partner, Morgan Lewis

Benjamin Smith
Partner, Morgan Lewis

David Yeary
Vice President, Merrill DataSite